Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its holdings in shares of Organon & Co. (NYSE:OGN) by 3.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,265,280 shares of the company’s stock after selling 118,860 shares during the quarter. Dimensional Fund Advisors LP owned 1.24% of Organon & Co. worth $19,553,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in OGN. Vanguard Group Inc. lifted its holdings in shares of Organon & Co. by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after acquiring an additional 987,979 shares in the last quarter. State Street Corp boosted its position in Organon & Co. by 2.8% during the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock worth $68,816,000 after purchasing an additional 262,185 shares during the period. AQR Capital Management LLC increased its holdings in Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Private Management Group Inc. increased its holdings in Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG raised its position in Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.1%

Shares of Organon & Co. stock opened at $13.55 on Friday. The business has a 50-day moving average of $13.49 and a 200-day moving average of $10.56. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.42. The company has a market capitalization of $3.56 billion, a PE ratio of 17.60, a P/E/G ratio of 1.26 and a beta of 1.55. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.60.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio is currently 10.39%.

Wall Street Analyst Weigh In

A number of brokerages have commented on OGN. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and raised their target price for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Organon & Co. has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.